Abstract:Objective Defined as prospective single‐patient crossover studies with repeated paired cycles of active and control intervention, N‐of‐1 trials have gained attention as an option to obtain high‐quality evidence of efficacy, particularly for patients with rare epilepsies in whom conduction of well‐powered randomized controlled trials can be challenging. The objective of this systematic review is to provide an appraisal of the literature on N‐of‐1 trials in individuals with epilepsy. Methods We searched PubMed and Embase on January 12, 2024, for studies meeting the following criteria: prospectively planned, within‐patient, multiple‐crossover design in individuals with epilepsy and outcomes related to comorbidities. Information on design, outcome measurements, intervention, and analyses was retrieved. Risk of bias assessment was performed using the Risk of Bias in N‐of‐1 Trials (RoBiNT) scale. We highlighted methodological aspects of the N‐of‐1 trials identified and discuss future recommendations. Results Five studies met our inclusion criteria. An additional multiple‐crossover trial that evaluated treatment effects exclusively at group level was also included because of its relevance to N‐of‐1 study methodology. The studies enrolled individuals with focal seizures, absences or cognitive impairement and electrographic discharges. Treatments included established or investigational antiseizure medications, off‐label medications, neurostimulation or lifestyle intervention. Three of the five N‐of‐1 trials reported on individual cases. The studies' strengths were the use of individualized treatment dosages and symptom‐specific patient‐reported outcomes. Limitations were related to minimal reporting of baseline characteristics and seizure burden. Significance The trials identified by our search exemplify how the N‐of‐1 design can be applied to assess interventions in individuals with epilepsy‐related disorders. Future N‐of‐1 trials of antiseizure interventions should take into account baseline seizure frequency, should apply statistical models suited to capture seizure frequency changes reliably and make predefined interim assessments. Non‐seizure outcome measures evaluable over short periods should be considered. Tailored N‐of‐1 methodology could pave the way to evidence‐based, treatment selection for patients with rare epilepsies.

The state-of-the-art of N -of-1 therapies and the IRDiRC N -of-1 development roadmap

A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives

Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases

N‐of‐1 trials in epilepsy: A systematic review and lessons paving the way forward

Nucleic Acid–Based Therapeutics in Orphan Neurological Disorders: Recent Developments

Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs

A qualitative study on the facilitators and barriers to adopting the N-of-1 trial methodology as part of clinical practice: potential versus implementation challenges

Lessons learned from the RE(ACT) conference on medical devices for rare diseases

Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook

Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges

Challenges of developing and conducting clinical trials in rare disorders

Consensus guidelines for eligibility assessment of pathogenic variants to antisense oligonucleotide treatments

Riding the gene therapy wave: challenges and opportunities for rare disease patients and clinicians

Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies

Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases

Joining forces to develop individualized antisense oligonucleotides for patients with brain or eye diseases: the example of the Dutch Center for RNA Therapeutics

Practical Recommendations for the Selection of Patients for Individualized Splice-Switching ASO-Based Treatments

A methodological review of randomised n-of-1 trials

The development of a set of key points to aid clinicians and researchers in designing and conducting n-of-1 trials

[Rare diseases: unraveling the biological bases to find future therapies]